The Demographic Time Bomb

The Demographic Time Bomb Nobody Wants to Talk About

Healthcare spending as a share of GDP has risen in virtually every developed country for thirty consecutive years. In the United States it now accounts for nearly 17% of economic output, more than any comparable nation, with outcomes that rank poorly against most of them. The UK NHS budget has grown from roughly £30 billion in 1997 to over £180 billion today. Japan, which has the oldest population of any major economy, is already spending over 11% of GDP on healthcare and the trajectory is pointing sharply upward.

Politicians in every one of these countries talk about their healthcare systems constantly. They almost never talk honestly about what is driving the cost. The inflation crisis made the cost of thirty years of deferred decisions visible almost overnight, in the price of food, fuel and everything else. The healthcare crisis is slower and quieter. But the arithmetic is no less brutal, and the bill is arriving now whether governments are ready to discuss it or not.

The Same Engine Behind the Inflation Story

To understand what is happening to healthcare costs, you need to start with the same demographic argument that explains the inflation story discussed in an earlier piece on this blog.

Economists Manoj Pradhan and Charles Goodhart argued in their work on the great demographic reversal that central banks spent thirty years taking credit for low inflation that was actually the product of a structural tailwind: the entry of the baby boom generation into the workforce, rising female labour participation, and the integration of China and Eastern Europe into global trade. This effectively doubled the global labour force, keeping wages and prices suppressed for decades. Central bankers mistook a structural gift for evidence of their own competence. Now the tailwind has reversed and the inflation is back.

The same logic applies to healthcare, and the reversal is just as structural.

The post-war baby boom produced an unusually large cohort of working-age adults who paid taxes into healthcare systems between roughly 1970 and 2010 while being young and healthy enough to use them relatively little. The ratio of contributors to claimants was favourable. Systems expanded. Politicians took credit for the generosity of the welfare states they were presiding over. And the underlying demographic conditions that made all of it affordable were treated as a permanent feature of the landscape rather than a temporary one.

By 2030, one in six people globally will be over 60. In Japan the figure is already closer to one in three. In Germany, Italy and South Korea the trajectories are similar. The workers who funded the system are becoming the patients the system has to treat, simultaneously, at a scale that no efficiency reform or technological optimism can fully offset.

What an Ageing Population Actually Costs

The core problem is not simply that older people use more healthcare. It is that they use dramatically more of the most expensive kind, and they are doing so all at once.

Research published in Health Services Research found that a disproportionate share of lifetime healthcare expenditure is concentrated in the final decade of life. The last year of life alone accounts for a striking fraction of total lifetime costs in most developed health systems. As the baby boom cohort enters that phase simultaneously, the cost curve does not bend upward gradually. It bends sharply, at exactly the moment when the working-age population funding the system through taxation is shrinking in relative terms.

Chronic disease is the mechanism through which this plays out in practice. Heart disease, type 2 diabetes, dementia, chronic obstructive pulmonary disease and various cancers account for around 75% of all healthcare spending in developed countries according to CDC data. These conditions are heavily age-correlated. More importantly, they increasingly appear together. A patient with three or four simultaneous chronic conditions is not three or four times as expensive as a healthy patient. Their conditions interact, their medication regimes are complex, and their care requires coordination across multiple specialties. The clinical term for this is multimorbidity, and its prevalence rises sharply with age. Research published in the Lancet found that by age 65, more than half of patients in a typical developed country primary care population have at least two chronic conditions. By 75, the majority have three or more.

Dementia sits at the extreme end of this cost curve and deserves particular attention, because there is no realistic near-term solution to it. The Alzheimer's Association estimates that the total cost of caring for people with Alzheimer's and other dementias in the US alone will reach $1 trillion annually by 2050. There is no cure. There is no drug that meaningfully slows progression for most patients. The care burden falls partly on health systems and partly on unpaid family carers, which creates a secondary economic drag as working-age adults reduce their labour market participation to provide care at home. That drag does not show up in healthcare budgets. It shows up in GDP, in tax revenues, and in the productivity statistics governments rely on to grow their way out of fiscal problems.

The Workforce Crisis Nobody Is Training For

The demographic shift is not just reshaping the patient population. It is hollowing out the workforce that treats them.

Healthcare workers are themselves ageing. In the US, the Association of American Medical Colleges projects a shortage of between 37,000 and 124,000 physicians by 2034, driven partly by the retirement of older doctors and partly by a training pipeline that takes the better part of a decade to produce a fully qualified clinician. You cannot fix a workforce shortage that has been building for twenty years with a single budget announcement or a targeted recruitment drive. The lead times are simply too long.

In the UK, NHS England was short of roughly 112,000 full-time equivalent staff as of 2024. That figure represents not a temporary gap but a structural deficit that has been widening for years. The same pattern appears across most of Western Europe, in Canada, in Australia and in Japan, where the combination of an ageing workforce and a shrinking pool of younger workers entering training creates a compounding problem rather than a static one.

Layered on top of the supply problem is a retention crisis that the pandemic accelerated but did not create. Burnout rates among healthcare workers were rising before Covid and surged during it. In the US, around 20% of healthcare workers left their jobs between 2020 and 2022. Many did not return. Those who stayed are on average older and closer to their own retirement. The NHS has been running significant numbers of staff on temporary and agency contracts to fill gaps left by permanent departures, which costs more per hour and provides less continuity of care. It is an expensive way to manage a structural problem and it does nothing to address the underlying shortage.

The workforce crisis interacts with the demographic patient surge in a particularly unfavourable way. Just as demand for healthcare is rising steeply, the supply of people available to provide it is under pressure from exactly the same demographic forces driving the demand. Both curves are moving in the wrong direction at the same time.

The Fiscal Trap

Healthcare spending is not just a health policy problem. It is a fiscal problem of the first order, and it connects directly to the broader argument about deficits, debt and central bank pressure that runs through the inflation piece.

In most developed countries, public healthcare is the single largest or second largest item of government expenditure. The UK Office for Budget Responsibility has warned repeatedly in its long-term fiscal projections that without significant structural reform, health and social care spending alone could push public debt to unsustainable levels within two decades. The Congressional Budget Office makes a similar projection for the United States, where Medicare and Medicaid already account for a larger share of federal spending than defence.

As the demand curve bends upward, governments face an impossible set of choices. Raise taxes on a shrinking working-age population to fund healthcare for a growing retired one. Cut other government spending at precisely the moment when geopolitical pressures are demanding more defence, more energy infrastructure and more supply chain redundancy. Borrow more and add to the structural deficits that, as Pradhan and Goodhart argue, will eventually force central banks to accommodate government spending in ways that fuel inflation. Or ration care, which is already happening quietly through waiting lists, staffing shortages and the gradual withdrawal of certain treatments from public coverage, without anyone using the word rationing in public.

All four options are politically toxic in ways that reinforce each other. Raising taxes on younger generations to fund the healthcare of older ones redistributes wealth in a direction that creates obvious political tensions, particularly in countries where younger people are already priced out of housing markets, carrying significant student debt and facing a labour market being reshaped by automation. The intergenerational dimension of this problem is not being discussed honestly in most political systems. It is being managed through euphemism and deferral.

Why Governments Have Not Fixed It

This is the most uncomfortable part of the argument, and it is worth being direct about it.

The demographic problem in healthcare has been clearly visible and exhaustively documented for at least thirty years. The OECD has been publishing warnings about ageing population pressures on health systems since the 1990s. Actuaries, health economists and public health researchers have been modelling the cost curves with reasonable accuracy for most of that period. The information was available. The analysis was done. The projections were largely correct.

And almost nothing structural was done about it.

The reason is political economy rather than ignorance, and it follows exactly the same logic as the central banking story. The costs of the current system are diffuse and future-oriented, while the costs of reform are immediate and concentrated. Cutting benefits, raising retirement ages, restricting coverage or shifting significant costs to users generates intense political opposition from a cohort, the baby boomers, that is the largest voting bloc in most developed democracies, turns out in high numbers at elections, and has strong opinions about the healthcare entitlements it has spent a working lifetime paying into.

Meanwhile, investing seriously in prevention rather than treatment produces benefits that materialise over decades and across multiple electoral cycles. Restructuring primary care to manage chronic disease more effectively requires sustained investment and institutional change that produces no visible results within a single parliamentary term. No politician running for office on a four or five year cycle has a strong incentive to take on the concentrated short-term pain of structural reform for diffuse long-term gains they will never personally get credit for.

The result is that every developed country has been running its healthcare system on borrowed time and borrowed money, hoping that incremental efficiency improvements, technological breakthroughs or sustained economic growth would somehow close the gap before it became a crisis. That hope is not entirely wrong. There have been genuine efficiency gains. Technology has delivered some real benefits. But the gap between what systems are expected to deliver and what they can realistically afford to provide has been widening steadily, and the demographic forces driving it are now accelerating.

What Comes Next

It would not be honest to close without acknowledging the technological optimism that runs through most mainstream discussion of healthcare costs, and it would not be honest to dismiss it entirely.

Artificial intelligence applied to diagnostics, administration and drug discovery has genuine potential to reduce certain categories of healthcare cost. GLP-1 drugs like Ozempic and Wegovy have produced striking results in clinical trials for obesity and cardiovascular risk reduction, and if they can meaningfully reduce the prevalence of obesity-related chronic disease over the next decade, the downstream savings could be substantial. Some countries have had genuine success in shifting investment toward prevention in ways that have reduced acute care demand over time.

The honest assessment is that none of these are solutions at the scale and speed the demographic pressure requires. AI adoption in healthcare is slow, uneven and raises significant questions about equity and implementation cost. GLP-1 drugs are currently expensive, supply-constrained, and require indefinite use to maintain their effects. Prevention, even where it works, takes decades to reduce acute care demand.

A problem that has been building for thirty years does not get solved by a drug that has been on the market for three.

The more likely near-term trajectory is continued cost pressure, continued quiet rationing through waiting lists and workforce shortages, and a series of periodic political crises as the gap between what systems are expected to deliver and what they can realistically provide becomes too wide to paper over. The UK is arguably already in this phase. The US is heading toward a Medicare fiscal reckoning that the Congressional Budget Office has been flagging for years and that neither party has a credible plan to address. Japan, with the oldest population of any major economy, is the canary in the coal mine for what this looks like when it fully arrives.

The inflation crisis made the cost of thirty years of deferred decisions visible almost overnight. The healthcare crisis will be slower and quieter. But the baby boomers are not getting younger. The workforce is not getting larger. The chronic disease burden is not going to stabilise on its own. And the governments responsible for managing all of this are operating in political systems that reward short-term thinking and punish exactly the kind of difficult structural reform that might actually help.